{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:37:59Z","timestamp":1792521479333,"version":"4.5.0"},"reference-count":103,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100030774","name":"Sociedade Brasileira de Reumatologia","doi-asserted-by":"publisher","award":["392 SBR2021SAFER001"],"award-info":[{"award-number":["392 SBR2021SAFER001"]}],"id":[{"id":"10.13039\/100030774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006506","name":"Minist\u00e9rio da Sa\u00fade","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006506","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014555","name":"Foundation for Scientific and Technological Development in Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014555","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background\/objectives<\/jats:title>\n                    <jats:p>Patients with systemic vasculitis faced the risk of severe COVID-19 and high mortality during the pandemic. Although SARS-CoV-2 vaccination mitigates these outcomes, vaccine hesitancy persists, and data on immunogenicity and safety in vasculitis is still limited. This study aims to assess response to primary and booster doses of SARS-CoV-2 vaccination in systemic vasculitis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicenter cohort study including systemic vasculitis included patients from SAFER study (Safety and Efficacy of COVID-19 Vaccines in Rheumatic Diseases). We evaluated serum IgG levels against the SARS-CoV-2 spike protein receptor-binding domain (IgG anti-RBD) at baseline and 28 days post-vaccination, disease activity scores, new cases of COVID-19 infections, and adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Seventy-three patients with systemic vasculitis were included. Beh\u00e7et\u2019s disease (n=39), Takayasu arteritis (n=15), and antineutrophil cytoplasmic antibody-associated vasculitis (n=14) were the most common vasculitis forms. The majority of the patients had no comorbidities and were in remission. Seventy patients received one, 65 two, and 60 three vaccine doses. ChAdOx1 nCoV-19 (AstraZeneca\/Oxford) (n=36) and CoronaVac (Sinovac) (n=25) were primarily the most common vaccines, while BNT162b2 (Pfizer\u2013BioNTech) was usually the booster vaccine. ChAdOx1 nCoV-19 induced higher IgG anti-RBD than CoronaVac after two doses (\n                      <jats:italic>p<\/jats:italic>\n                      =0.002), but this difference disappeared after the booster dose. No differences in vaccine response were noted between heterologous and homologous regimens or vasculitis types. The new cases of COVID-19 (16.9%), hospitalization (1.5%), and mortality (1.5%) rates were relatively low following vaccination. Disease activity remained stable, and adverse events were mostly mild. Only one severe adverse event was observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Different SARS-CoV-2 vaccines demonstrated immunogenicity and clinical effectiveness in systemic vasculitis. The three-dose schedule was safe without increasing relapse risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1655917","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T06:26:17Z","timestamp":1763360777000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Immunogenicity and safety to SARS-Cov-2 vaccination in patients with systemic vasculitis"],"prefix":"10.3389","volume":"16","author":[{"given":"Erika","family":"Biegelmeyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"de Freitas Aguiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscila","family":"Dias Cardoso Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketty Lysie Libardi Lira","family":"Machado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila Maria","family":"Paiva Fran\u00e7a Telles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra L\u00facia","family":"Euz\u00e9bio Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nat\u00e1lia","family":"Sarzi Sartori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Poubel Vieira de Rezende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Karla","family":"Guedes de Melo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vitor","family":"Alves Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rejane Maria","family":"Rodrigues de Abreu Vieira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana Maria","family":"Kakehasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cec\u00edlia","family":"Dias Corr\u00eaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valderilio Feij\u00f3","family":"Azevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olindo Assis","family":"Martins-Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fl\u00e1via Maria","family":"Matos Melo Campos Peixoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"de Oliveira Magalh\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria da Penha","family":"Gomes Gouveia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tha\u00eds Evelyn","family":"Karnopp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Lino Baptista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T\u00e2mara","family":"Santos Melo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jozelia","family":"R\u00eago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adah Sophia","family":"Rodrigues Vieira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Carolina","family":"Faria Moreira Gomes Tavares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vict\u00f3ria","family":"Dornelas Paz Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Peruhype-Magalh\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laiza Hombre","family":"Dias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Lima de Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly Rossana","family":"da Silva Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nat\u00e1lia","family":"Rodrigues Querido Fortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9bora","family":"Marques Veghini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f4natas Almeida","family":"Amorim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raiza Casian","family":"Tu\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina Rosemarie","family":"Lallemand Tapia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiane","family":"Kayser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlles Heldan de Moura","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maressa","family":"Barbosa Beloni Lirio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"B\u00fchring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo Machado","family":"Xavier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9a","family":"Teixeira-Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viviane","family":"Angelina de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odirlei Andr\u00e9","family":"Monticielo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilda Aparecida","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo de Medeiros","family":"Pinheiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgard","family":"Torres dos Reis Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia Inoue","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Valim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gecilmara Salviato","family":"Pileggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre Wagner Silva","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.211012","article-title":"COVID-19 hospitalizations, intensive care unit stays, ventilation, and death among patients with immune-mediated inflammatory diseases compared to controls","volume":"49","author":"Eder","year":"2022","journal-title":"J Rheumatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221575","article-title":"Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations","volume":"81","author":"Kroon","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05301-2","article-title":"Determinants of COVID-19 disease severity in patients with underlying rheumatic disease","volume":"39","author":"Santos","year":"2020","journal-title":"Clin Rheumatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001461corr1","article-title":"High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: First results of ReumaCoV Brasil registry","volume":"7","author":"Marques","year":"2021","journal-title":"RMD Open"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1186\/s42358-022-00244-5","article-title":"Factors associated with hospitalizations for Covid-19 in patients with rheumatoid arthritis: data from the Reumacov Brazil registry","volume":"62","author":"Gomides","year":"2022","journal-title":"Adv Rheumatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221636","article-title":"Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance","volume":"81","author":"Ugarte-Gil","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00296-022-05229-7","article-title":"COVID-19 severity and vaccine breakthrough infections in idiopathic inflammatory myopathies, other systemic autoimmune and inflammatory diseases, and healthy controls: a multicenter cross-sectional study from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) survey","volume":"43","author":"Hoff","year":"2023","journal-title":"Rheumatol Int"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/art.41728","article-title":"Risk factors for severe outcomes in patients with systemic vasculitis and COVID-19: A binational, registry-based cohort study","volume":"73","author":"Rutherford","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-022-05177-2","article-title":"Managing ANCA-associated vasculitis during COVID-19 pandemic: a single-center cross-sectional study","volume":"42","author":"Samanta","year":"2022","journal-title":"Rheumatol Int"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1080\/03009742.2022.2109337","article-title":"Risks and treatment related aspects of COVID-19 infection in patients with ANCA-associated vasculitis","volume":"52","author":"Antovic","year":"2023","journal-title":"Scand J Rheumatol"},{"key":"B11","doi-asserted-by":"crossref","DOI":"10.1016\/S2665-9913(21)00316-7","article-title":"Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study","volume":"3","author":"Sattui","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.berh.2018.10.003","article-title":"Introduction, epidemiology and classification of vasculitis","volume":"32","author":"Watts","year":"2018","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-021-06032-8","article-title":"Different epidemiologic profiles of systemic vasculitis between Brazil and Peru-preliminary results in two referral centers from both countries","volume":"41","author":"de Souza","year":"2022","journal-title":"Clin Rheumatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000001964","article-title":"The epidemiology of takayasu arteritis in Rio de Janeiro, Brazil: A large population-based study","volume":"29","author":"Vieira","year":"2023","journal-title":"J Clin Rheumatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex293","article-title":"Global ethnic and geographic differences in the clinical presentations of anti-neutrophil cytoplasm antibody-associated vasculitis","volume":"56","author":"Pearce","year":"2017","journal-title":"Rheumatol (Oxford)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41584-021-00718-8","article-title":"Global epidemiology of vasculitis","volume":"18","author":"Watts","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key285","article-title":"Mortality and causes of death across the systemic connective tissue diseases and the primary systemic vasculitides","volume":"58","author":"Garen","year":"2019","journal-title":"Rheumatol (Oxford)"},{"key":"B18","first-page":"S94","article-title":"Mortality in systemic vasculitis: a systematic review","volume":"26","author":"Phillip","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1186\/s42358-022-00234-7","article-title":"Guidelines on COVID-19 vaccination in patients with immune-mediated rheumatic diseases: a Brazilian Society of Rheumatology task force","volume":"62","author":"Tavares","year":"2022","journal-title":"Adv Rheumatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0275699","article-title":"The impact of COVID-19 vaccination in the US: Averted burden of SARS-COV-2-related cases, hospitalizations and deaths","volume":"18","author":"Yamana","year":"2023","journal-title":"PloS One"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32458-y","article-title":"Trends in COVID-19 hospital outcomes in England before and after vaccine introduction, a cohort study","volume":"13","author":"Kirwan","year":"2022","journal-title":"Nat Commun"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-069317","article-title":"Public health impact of covid-19 vaccines in the US: observational study","volume":"377","author":"Suthar","year":"2022","journal-title":"BMJ"},{"key":"B23","doi-asserted-by":"publisher","first-page":"96","DOI":"10.2105\/AJPH.2022.307112","article-title":"SARS-CoV-2 infection, hospitalization, and death in vaccinated and infected individuals by age groups in Indiana, 2021\u20132022","volume":"113","author":"Tu","year":"2023","journal-title":"Am J Public Health"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/5931506","article-title":"COVID-19 vaccination intention and vaccine hesitancy among patients with autoimmune and autoinflammatory rheumatological diseases: A survey","volume":"2022","author":"Tharwat","year":"2022","journal-title":"Int J Clin Pract"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/rai2.12028","article-title":"The COVID-19 vaccine: Attitudes and vaccination in patients with autoimmune inflammatory rheumatic diseases","volume":"2","author":"Chen","year":"2022","journal-title":"Rheumatol Autoimmun"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.09.057","article-title":"Characteristics associated with COVID-19 vaccine hesitancy: A nationwide survey of 1000 patients with immune-mediated inflammatory diseases","volume":"39","author":"Vieira Rezende","year":"2021","journal-title":"Vaccine"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1301492","article-title":"Understanding COVID-19 vaccine hesitancy in vasculitis patients","volume":"11","author":"Butt","year":"2023","journal-title":"Front Public Health"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1030810","article-title":"COVID-19 vaccine uptake, hesitancy and clinical effects on patients with Takayasu\u2019s arteritis: A web-based questionnaire survey from a large cohort","volume":"14","author":"Kong","year":"2023","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3390\/vaccines10050653","article-title":"Dual-positive MPO- and PR3-ANCA-associated vasculitis following SARS-CoV-2 mRNA booster vaccination: A case report and systematic review","volume":"10","author":"Baier","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-024-05718-x","article-title":"Onset of leukocytoclastic vasculitis following covid-19 vaccination: case based comprehensive review","volume":"44","author":"Miskovic","year":"2024","journal-title":"Rheumatol Int"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-024-02217-w","article-title":"Post COVID-19 vaccination medium vessel vasculitis: a systematic review of case reports","volume":"52","author":"Sanker","year":"2024","journal-title":"Infection"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac323\/6596033","article-title":"Risk of systemic vasculitis following mRNA COVID-19 vaccination: a pharmacovigilance study","volume":"61","author":"Mettler","year":"2022","journal-title":"Rheumatology"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2334084","article-title":"Polymyalgia rheumatica and giant cell arteritis following COVID-19 vaccination: Results from a nationwide survey","volume":"20","author":"Jarrot","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.220629","article-title":"COVID-19 vaccination as a trigger of IgA vasculitis: A global pharmacovigilance study","volume":"50","author":"Ramdani","year":"2023","journal-title":"J Rheumatol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1136\/annrheumdis-2021-221490","article-title":"Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry","volume":"81","author":"MaChado","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-222498","article-title":"Severely impaired humoral response against SARS-CoV-2 variants of concern following two doses of BNT162b2 vaccine in patients with systemic lupus erythematosus (SLE)","volume":"81","author":"Mageau","year":"2022","journal-title":"Ann Rheumatic Dis"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac089","article-title":"Humoral and cellular response to COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases under real-life conditions","volume":"61","author":"Krasselt","year":"2022","journal-title":"Rheumatology"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-021-01046-2","article-title":"The use of COVID-19 vaccines in patients with SLE","volume":"23","author":"Tang","year":"2021","journal-title":"Curr Rheumatol Rep"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2022-elm2022.188","article-title":"Immune responses to mRNA vaccines against SARS-CoV-2 in patients with immune-mediated inflammatory rheumatic diseases","volume":"8","author":"Sieiro Santos","year":"2022","journal-title":"RMD Open"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s42358-024-00397-5","article-title":"Safety of CoronaVac and ChAdOx1 vaccines against SARS-CoV-2 in patients with rheumatoid arthritis: data from the Brazilian multicentric study safer","volume":"64","author":"Cruz","year":"2024","journal-title":"Adv Rheumatol"},{"key":"B41","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.3390\/vaccines12091031","article-title":"Predictors of hospitalization in breakthrough COVID-19 among fully vaccinated individuals with immune-mediated rheumatic diseases: data from SAFER-study","volume":"12","author":"Calderaro","year":"2024","journal-title":"Vaccines"},{"key":"B42","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.3390\/vaccines12121367","article-title":"Immunogenicity and safety according to immunosuppressive drugs and different COVID-19 vaccine platforms in immune-mediated disease: data from SAFER cohort","volume":"12","author":"MaChado","year":"2024","journal-title":"Vaccines"},{"key":"B43","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3390\/vaccines13020127","article-title":"Immunogenicity of SARS-CoV-2 vaccination schedules including a booster dose in patients with systemic lupus erythematosus: data from a prospective multicenter study","volume":"13","author":"Sartori","year":"2025","journal-title":"Vaccines (Basel)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2025.106920","article-title":"Effectiveness and immunogenicity of SARS-CoV-2 booster vaccine in immunosuppressed systemic autoimmune disease patients: A prospective study","volume":"164","author":"Teles","year":"2025","journal-title":"Med Clin (Barc)"},{"key":"B45","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2021-221747","article-title":"Third COVID-19 vaccine dose with BNT162b2 in patients with ANCA-associated vasculitis","volume":"81","author":"Speer","year":"2022","journal-title":"Ann rheumatic Dis"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.11.012","article-title":"Antibody response to COVID-19 booster vaccine in rituximab-treated patients with anti\u2013neutrophil cytoplasmic antibody\u2013associated vasculitis","volume":"101","author":"Kant","year":"2022","journal-title":"Kidney Int"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinsp.2022.100150","article-title":"Anti-SARS-CoV-2 inactivated vaccine in patients with ANCA-associated vasculitis: Immunogenicity, safety, antibody decay and the booster dose","volume":"78","author":"Pereira","year":"2023","journal-title":"Clinics"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1146841","article-title":"Cellular and humoral responses after second and third SARS-CoV-2 vaccinations in patients with autoimmune diseases treated with rituximab: specific T cell immunity remains longer and plays a protective role against SARS-CoV-2 reinfections","volume":"14","author":"Egri","year":"2023","journal-title":"Front Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.834981","article-title":"Antigen specific humoral and cellular immunity following SARS-CoV-2 vaccination in ANCA-associated vasculitis patients receiving B-cell depleting therapy","volume":"13","author":"Marty","year":"2022","journal-title":"Front Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.817845","article-title":"Response to vaccination against SARS-CoV-2 in patients with antineutrophil cytoplasmic antibody-associated vasculitis with renal involvement","volume":"8","author":"Carruthers","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2021.12.004","article-title":"SARS-CoV-2 vaccine response in patients with antineutrophil cytoplasmic autoantibody-associated vasculitis","volume":"7","author":"Floyd","year":"2022","journal-title":"Kidney Int Rep"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220647","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: A multicentre study","volume":"80","author":"Furer","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-022-05164-7","article-title":"Higher antibody responses after mRNA-based vaccine compared to inactivated vaccine against SARS-CoV-2 in Behcet\u2019s syndrome","volume":"42","author":"Ozdede","year":"2022","journal-title":"Rheumatol Int"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-022-05119-y","article-title":"Safety of SARS-CoV-2 vaccination in patients with Behcet\u2019s syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine","volume":"42","author":"Ozdede","year":"2022","journal-title":"Rheumatol Int"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14387","article-title":"Effects of anti-SARS-CoV-2 vaccination on safety and disease exacerbation in patients with Beh\u00e7et syndrome in a monocentric cohort","volume":"25","author":"Apaydin","year":"2022","journal-title":"Int J Rheum Dis"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac365","article-title":"Immunosuppressive treatments selectively affect the humoral and cellular response to SARS-CoV-2 in vaccinated patients with vasculitis","volume":"62","author":"Monti","year":"2023","journal-title":"Rheumatol (Oxford)"},{"key":"B57","doi-asserted-by":"publisher","first-page":"853","DOI":"10.55563\/clinexprheumatol\/xj2pqk","article-title":"Safety of BNT162b2 mRNA COVID-19 vaccine in a cohort of elderly, immunocompromised patients with systemic vasculitis","volume":"40","author":"Delvino","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"942","DOI":"10.55563\/clinexprheumatol\/mlatyf","article-title":"Humoral and T-cell immune response following three doses of SARS-CoV-2 mRNA vaccine in giant cell arteritis: analysis of a prospective cohort","volume":"42","author":"Bartoletti","year":"2024","journal-title":"Clin Exp Rheumatol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1002\/acr.25173","article-title":"Humoral SARS-CoV-2 vaccine responses in patients with giant cell arteritis and polymyalgia rheumatica: decay after primary vaccination and effects of the booster","volume":"76","author":"van Sleen","year":"2024","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.55730\/1300-0144.5347","article-title":"The effect of COVID-19 pandemic in a large series of patients with Takayasu arteritis","volume":"52","author":"Karaka\u015f","year":"2022","journal-title":"Turk J Med Sci"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221248","article-title":"Flares of mixed cryoglobulinaemia vasculitis after vaccination against SARS-CoV-2","volume":"81","author":"Visentini","year":"2022","journal-title":"Ann rheumatic Dis"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/ldv88a","article-title":"COVID-19 vaccination rate and safety profile in a multicentre Italian population affected by mixed cryoglobulinaemic vasculitis","volume":"41","author":"Vacchi","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"B63","article-title":"Safety evaluation of COVID-19 vaccine in patients with IgA nephropathy or IgA vasculitis nephritis","volume":"7","author":"Zan","year":"2022","journal-title":"Kidney Int Rep"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1111\/imj.16343","article-title":"The impact of coronavirus-19 vaccination on anti-nuclear cytoplasmic antibody vasculitis hospitalisations in a Sydney health network","volume":"54","author":"Turner","year":"2024","journal-title":"Intern Med J"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102846","article-title":"COVID-19: Clinical features and outcomes in unvaccinated 2-dose and 3-dose vaccinated against SARS-CoV-2 patients with systemic autoimmune and autoinflammatory rheumatic diseases","volume":"131","author":"Bakasis","year":"2022","journal-title":"J Autoimmun"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780330811","article-title":"The American College of Rheumatology 1990 criteria for the classification of takayasu arteritis","volume":"33","author":"Arend","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B67","article-title":"Criteria for diagnosis of Behcet\u2019s disease","volume":"335","year":"1990","journal-title":"Lancet"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 Revised International Chapel Hill consensus conference nomenclature of vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.054593","article-title":"Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies","volume":"66","author":"Watts","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu271","article-title":"Validation of the classification criteria for cryoglobulinaemic vasculitis","volume":"53","author":"Quartuccio","year":"2014","journal-title":"Rheumatology"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780330809","article-title":"The American College of Rheumatology 1990 criteria for the classification of henoch-sch\u00f6nlein purpura","volume":"33","author":"Mills","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780330810","article-title":"The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis","volume":"33","author":"Hunder","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-5273(98)00175-2","article-title":"Diagnostic criteria of Buerger\u2019s disease","author":"Shionoya","year":"1998","journal-title":"Int J Cardiol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/00005792-198801000-00002","article-title":"Primary angiitis of the central nervous system: Report of 8 new cases, review of the literature, and proposal for diagnostic criteria","volume":"67","author":"Calabrese","year":"1988","journal-title":"Med (United States)"},{"key":"B75","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s42358-019-0056-x","article-title":"Brazilian recommendations on the safety and effectiveness of the yellow fever vaccination in patients with chronic immune-mediated inflammatory diseases","volume":"59","author":"Pileggi","year":"2019","journal-title":"Adv Rheumatol"},{"key":"B76","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1590\/S0482-50042013000100002","article-title":"Consenso 2012 da Sociedade Brasileira de Reumatologia sobre vacina\u00e7\u00e3o em pacientes com artrite reumatoide","volume":"53","author":"Brenol","year":"2013","journal-title":"Rev Bras Reumatol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa344","article-title":"Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019","volume":"71","author":"Zhao","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.101279","article-title":"Modification and validation of the Birmingham vasculitis activity score (version 3)","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"B79","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1590\/S0482-50042009000100003","article-title":"Adapta\u00e7\u00e3o transcultural da vers\u00e3o simplificada (s) do Beh\u00e7et\u2019s Disease Current Activity Form (BDCAF) e compara_\u0327tiao do desempenho das vers\u00f5es Brasileiras dos dois instrumentos de avalia\u00e7\u00e3o da atividade da Doen\u00e7a de Beh\u00e7et: BR-BDCAF e BR-BDCAF(s)","volume":"49","author":"Neves F de","year":"2009","journal-title":"Rev Bras Reumatol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-120-11-199406010-00004","article-title":"Takayasu arteritis","volume":"120","author":"Kerr","year":"1994","journal-title":"Ann Intern Med"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10060853","article-title":"Comparison of immunogenicity and safety of inactivated, adenovirus-vectored, and heterologous adenovirus-vectored\/mRNA vaccines in patients with systemic lupus erythematosus and rheumatoid arthritis: A prospective cohort study","volume":"10","author":"Assawasaksakul","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac976","article-title":"Severe acute respiratory syndrome coronavirus 2 infection history and antibody response to 3 Coronavirus disease 2019 messenger RNA vaccine doses","volume":"76","author":"Herring","year":"2023","journal-title":"Clin Infect Dis"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28679","article-title":"Longer intervals between SARS-CoV-2 infection and mRNA-1273 doses improve the neutralization of different variants of concern","volume":"95","author":"Garc\u00eda-P\u00e9rez","year":"2023","journal-title":"J Med Virol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.02981-23","article-title":"The serological immunogenicity of the third and fourth doses of COVID-19 vaccine in patients with inflammatory rheumatic diseases on different biologic or targeted DMARDs: a Swedish nationwide study (COVID-19-REUMA)","volume":"12","author":"Frodlund","year":"2024","journal-title":"Microbiol Spectr"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1187880","article-title":"Immune response of heterologous versus homologous prime-boost regimens with adenoviral vectored and mRNA COVID-19 vaccines in immunocompromised patients","volume":"14","author":"Chu","year":"2023","journal-title":"Front Immunol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231911411","article-title":"Comparison of homologous and heterologous booster SARS-CoV-2 vaccination in autoimmune rheumatic and musculoskeletal patients","volume":"23","author":"Honfi","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12050468","article-title":"A Comparison of the Immunogenicity and Safety of an Additional Heterologous versus Homologous COVID-19 Vaccination among Non-Seroconverted Immunocompromised Patients after a Two-Dose Primary Series of mRNA Vaccination: A Systematic Review and Meta-Analysis","volume":"12","author":"Nangsue","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1427501","article-title":"4th booster-dose SARS-CoV-2 heterologous and homologous vaccination in rheumatological patients","volume":"15","author":"Gallardo-Nelson","year":"2024","journal-title":"Front Immunol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"E9","DOI":"10.1097\/RHU.0000000000002038","article-title":"Factors associated with mortality in patients with immune-mediated rheumatic diseases and COVID-19 from Latin America: data from Argentina, Mexico, and Brazil","volume":"30","author":"Isnardi","year":"2024","journal-title":"J Clin Rheumatol"},{"key":"B90","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-002187","article-title":"SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry","volume":"8","author":"Liew","year":"2022","journal-title":"RMD Open"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221916","article-title":"Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial","volume":"81","author":"Araujo","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221735","article-title":"Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis","volume":"81","author":"Medeiros-Ribeiro","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10050801","article-title":"Dose-dependent impairment of the immune response to the moderna-1273 mRNA vaccine by mycophenolate mofetil in patients with rheumatic and autoimmune liver diseases","volume":"10","author":"De Santis","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kead275","article-title":"Immunosuppressive therapy and humoral response to third mRNA COVID-19 vaccination with a six-month interval in rheumatic disease patients","volume":"63","author":"Kashiwado","year":"2024","journal-title":"Rheumatol (Oxford)"},{"key":"B95","doi-asserted-by":"crossref","first-page":"901","DOI":"10.3390\/vaccines10060901","article-title":"Predictors of immunogenic response to the BNT162b2 mRNA COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases treated with rituximab","volume":"10","author":"Furer","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2021.102744","article-title":"Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients\u2019 subgroups","volume":"125","author":"Ferri","year":"2021","journal-title":"J Autoimmun"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102927","article-title":"Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: Systematic review and meta-analysis","volume":"21","author":"Jena","year":"2022","journal-title":"Autoimmun Rev"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220503","article-title":"Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2","volume":"80","author":"Braun-Moscovici","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217600","article-title":"Impact of COVID-19 pandemic on patients with large-vessel vasculitis in Italy: a monocentric survey","volume":"79","author":"Tomelleri","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B100","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2020-219407","article-title":"Correspondence on \u2018Impact of COVID-19 pandemic on patients with large-vessels vasculitis in Italy: a monocentric survey.\u2019","volume":"82","author":"Comarmond","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B101","article-title":"American college of rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 3","volume":"73","author":"Curtis","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/if8nka","article-title":"Multicentre case-control study evaluating the safety of anti-SARS-CoV-2 vaccines in a cohort of patients with systemic vasculitis","volume":"41","author":"Simoncelli","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01382","article-title":"Planned yellow fever primary vaccination is safe and immunogenic in patients with autoimmune diseases: A prospective non-interventional study","volume":"11","author":"Valim","year":"2020","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1655917\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T06:26:20Z","timestamp":1763360780000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1655917\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":103,"alternative-id":["10.3389\/fimmu.2025.1655917"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1655917","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"article-number":"1655917"}}